PAREXEL?S NORTH AMERICAN MEDICAL SERVICES APPOINTS EXPERTS TO THERAPEUTIC TEAM

BOSTON, MA, September 30, 2002 — PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest biopharmaceutical outsourcing companies, today announced the addition of three scientific leaders to its North American Medical Services (NAMS) Division. Michael F. DeBruin, M.D. joins PAREXEL as a Senior Medical Director specializing in Internal Medicine and Infectious Diseases. Judith A. Johnson, M.D. and Jennifer A. Larsen, M.D. will each serve as Associate Medical Directors. All will be based at PAREXEL’s headquarters in Waltham, MA.

Dr. DeBruin is a graduate of New York Medical College. Board-certified in Internal Medicine, he received certification in Infectious Diseases after training at the University of Connecticut Health Center. Upon obtaining his medical licensure, Dr. DeBruin held several director-level positions at Pfizer Central Research. He was later appointed Director of Clinical Research at Genetics Institute (now Wyeth-Ayerst), until 1998, when he assumed the role of Therapeutic Area Head for Infectious Diseases at Wyeth-Ayerst. Prior to joining PAREXEL, Dr. DeBruin was Vice President of Clinical Research and Development at Cubist Pharmaceuticals in Lexington, MA. In this position, he was responsible for the worldwide development campaign for lead antibiotic products.

Dr. Johnson is a general ophthalmologist who earned her medical degree at the University of Pennsylvania and completed her training at George Washington University Medical Center. Dr. Johnson has been active in clinical practice for over 15 years at Harvard Vanguard Medical Associates, Massachusetts Eye and Ear Infirmary and Mt. Auburn Ophthalmologic Associates in Cambridge, MA. Most recently, Dr. Johnson was responsible for the medical and surgical management of ocular disease.

A graduate of Smith College and the University of Cincinnati, College of Medicine, Dr. Larsen is a board-certified internist in Cardiology. Her extensive cardiology training includes fellowships in electrophysiology, echocardiography, general cardiology, and molecular biology. She held the position of Instructor in Medicine at Northwestern Memorial Hospital and Brigham and Women’s Hospital in Boston, MA for several years before joining PAREXEL.

“The appointment of Drs. DeBruin, Johnson, and Larsen will further enhance our scientific perspective in Infectious Diseases, Ophthalmology, and Cardiology,” stated Warren Stern, Ph.D., Senior Vice President of PAREXEL’s Scientific and Medical Services Unit. “We welcome Michael, Judith, and Jennifer to our community of biopharmaceutical experts and look forward to the application of their combined knowledge for the benefit of PAREXEL’s clients.”

PAREXEL is one of the largest pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 56 locations throughout 37 countries around the world, and has approximately 4,930 employees.

This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic and political risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the period ended June 30, 2002, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company disclaims any duty to update any of the forward-looking statements contained in this press release.